These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 10100709

  • 1. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
    Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ.
    Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
    [Abstract] [Full Text] [Related]

  • 2. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
    Dellas A, Schultheiss E, Almendral AC, Gudat F, Oberholzer M, Feichter G, Moch H, Torhorst J.
    Int J Cancer; 1997 Aug 22; 74(4):421-5. PubMed ID: 9291432
    [Abstract] [Full Text] [Related]

  • 3. The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer.
    Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG.
    Hum Pathol; 2010 Dec 22; 41(12):1735-41. PubMed ID: 21078436
    [Abstract] [Full Text] [Related]

  • 4. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
    Nishio S, Ushijima K, Yamaguchi T, Sasajima Y, Tsuda H, Kasamatsu T, Kage M, Ono M, Kuwano M, Kamura T.
    Gynecol Oncol; 2014 Mar 22; 132(3):703-8. PubMed ID: 24486603
    [Abstract] [Full Text] [Related]

  • 5. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarz M, Göppinger A, Pfleiderer A.
    Cancer; 1995 Jul 01; 76(1):57-66. PubMed ID: 8630877
    [Abstract] [Full Text] [Related]

  • 6. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E.
    Pathol Res Pract; 1997 Jul 01; 193(11-12):767-75. PubMed ID: 9521509
    [Abstract] [Full Text] [Related]

  • 7. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
    Ueno S, Sudo T, Oka N, Wakahashi S, Yamaguchi S, Fujiwara K, Mikami Y, Nishimura R.
    Int J Gynecol Cancer; 2013 Jul 01; 23(6):1084-91. PubMed ID: 23792604
    [Abstract] [Full Text] [Related]

  • 8. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN.
    Brewer CA, Liao SY, Wilczynski SP, Pastorekova S, Pastorek J, Zavada J, Kurosaki T, Manetta A, Berman ML, DiSaia PJ, Stanbridge EJ.
    Gynecol Oncol; 1996 Dec 01; 63(3):337-44. PubMed ID: 8946869
    [Abstract] [Full Text] [Related]

  • 9. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
    Skomedal H, Kristensen GB, Lie AK, Holm R.
    Gynecol Oncol; 1999 May 01; 73(2):223-8. PubMed ID: 10329038
    [Abstract] [Full Text] [Related]

  • 10. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis.
    Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC.
    Tumour Biol; 2001 May 01; 22(3):176-83. PubMed ID: 11275796
    [Abstract] [Full Text] [Related]

  • 11. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
    Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT.
    Int J Gynecol Cancer; 2005 May 01; 15(4):646-56. PubMed ID: 16014119
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB, Holm R, Abeler VM, Tropé CG.
    Cancer; 1996 Aug 01; 78(3):433-40. PubMed ID: 8697388
    [Abstract] [Full Text] [Related]

  • 13. Correlation p53 expression and human papilloma virus deoxyribonucleic acid with clinical outcome in early uterine cervical carcinoma.
    Ikuta A, Saito J, Mizokami T, Nakamoto T, Yasuhara M, Nagata F, Nakajima M, Matsuo I, Yasuda K, Kanzaki H.
    Cancer Detect Prev; 2005 Aug 01; 29(6):528-36. PubMed ID: 16289387
    [Abstract] [Full Text] [Related]

  • 14. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms.
    Dellas A, Schultheiss E, Leivas MR, Moch H, Torhorst J.
    Anticancer Res; 1998 Aug 01; 18(6A):3991-8. PubMed ID: 9891436
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.
    Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C.
    Am J Obstet Gynecol; 2017 Oct 01; 217(4):432.e1-432.e17. PubMed ID: 28599900
    [Abstract] [Full Text] [Related]

  • 16. Abnormal expression of pan-ras, c-myc and tp53 in squamous cell carcinoma of cervix: correlation with HPV and prognosis.
    Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC.
    Oncol Rep; 2001 Oct 01; 8(3):557-61. PubMed ID: 11295080
    [Abstract] [Full Text] [Related]

  • 17. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.
    Lee CM, Lee RJ, Hammond E, Tsodikov A, Dodson M, Zempolich K, Gaffney DK.
    Gynecol Oncol; 2004 Apr 01; 93(1):209-14. PubMed ID: 15047238
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis AN, Kittas C.
    Mod Pathol; 1996 May 01; 9(5):544-54. PubMed ID: 8733770
    [Abstract] [Full Text] [Related]

  • 19. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer.
    Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ.
    Histol Histopathol; 2000 Apr 01; 15(2):455-62. PubMed ID: 10809364
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M, Barrois M, Terrier MJ, Spielmann M, Riou G.
    Oncogene Res; 1988 Apr 01; 3(1):21-31. PubMed ID: 2905033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.